In early July, seven more Humira® (adalimumab) biosimilars, including a single interchangeable, joined Amjevita™ (adalimumab-atto) on the US market. Abrilada™ (adalimumab-afzb) remains the sole FDA-approved adalimumab biosimilar yet to be launched, despite predictions for an early release as of July 2023. The addition of these new biosimilars is poised to shake up the market considerably for adalimumab, a drug commonly used for the treatment of chronic inflammations.
The entry of these new biosimilars presents competition on a previously monopolized stage. However, it also raises several questions. As adalimumab biosimilars slowly saturate the market, how will the legal landscape react in response to the arrival of these newcomers? Equally important is a deeper investigation into the implications of these events for both manufacturers and potential consumers alike.
While the entry of multiple adalimumab biosimilars into the market might encourage cost reductions, sustained savings would need careful legal scrutiny. Issues such as patent infringement, oftentimes a hurdle in the biosimilar’s market, could potentially lead to litigation, putting these promising price drops at risk.
Moreover, the entrance of biosimilars that are interchangeable with Humira® presents a unique situation. Laws regarding pharmacists’ ability to swap prescriptions to interchangeable biosimilars vary regionally, making the situation even more convoluted legally. A meticulous watch on legislation as well as possible policy changes will thus be crucial for organizations interacting with this evolving sector.
Still, an insightful forecast of these unfolding occurrences requires further research and expert discussions to deliver effective strategies for stakeholders. Therefore, a detailed look into this matter is recommended, and you can find a vigorous examination on this topic by reviewing Venable LLP’s coverage.